Avacta hails data for faridoxorubicin to treat salivary gland cancers
(Alliance News) - Avacta Group PLC on Monday said its lead programme faridoxorubicin showed favourable safety and tolerability in patients with salivary gland cancers. Read More
| Price | 78.50p on 26-11-2025 at 18:30:05 |
|---|---|
| Change | 1.60p 2.08% |
| Buy | 80.00p |
| Sell | 77.00p |
| Last Trade: | Unknown 74,700.00 at 78.50p |
| Day's Volume: | 2,219,242 |
| Last Close: | 78.50p |
| Open: | 75.50p |
| ISIN: | GB00BYYW9G87 |
| Day's Range | 78.00p - 80.50p |
| 52wk Range: | 27.25p - 83.20p |
| Market Capitalisation: | £340.43m |
| VWAP: | 78.33753p |
| Shares in Issue: | 433.66m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Avacta Group (AVCT) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 74,700 | 78.50p | OTC Trade |
17:09:21 - 26-Nov-25 |
| Buy* | 17,345 | 79.00p | Ordinary |
16:40:55 - 26-Nov-25 |
| Buy* | 884 | 79.10p | Ordinary |
16:29:49 - 26-Nov-25 |
| Sell* | 14,500 | 78.4181p | Ordinary |
16:27:12 - 26-Nov-25 |
| Sell* | 6,370 | 78.422p | Ordinary |
16:21:48 - 26-Nov-25 |
| Sell* | 250 | 78.4961p | Ordinary |
16:16:10 - 26-Nov-25 |
| Buy* | 10,000 | 79.25p | Ordinary |
16:11:09 - 26-Nov-25 |
| Sell* | 1,258 | 78.4961p | Ordinary |
16:01:48 - 26-Nov-25 |
| Sell* | 7,693 | 78.05p | Ordinary |
15:55:47 - 26-Nov-25 |
| Sell* | 1,949 | 77.60p | Ordinary |
15:47:10 - 26-Nov-25 |
Avacta Group (AVCT) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 3rd Nov 2025 8:24 am | RNS | Completion of Placing and TVR |
| 27th Oct 2025 5:39 pm | RNS | Block Listing Six Monthly Return |
| 27th Oct 2025 7:00 am | RNS | Avacta presents preclinical data at AACR-NCI-EORTC |
| 23rd Oct 2025 5:00 pm | RNS-R | Notice of Investor Presentation |
| 20th Oct 2025 7:01 am | RNS | Equity fundraise of £16 million |
| 20th Oct 2025 7:00 am | RNS | Avacta Presents Phase 1a Data for Faridoxorubicin |
| 13th Oct 2025 7:00 am | RNS | Avacta to present data at EORTC-NCI-AACR |
| 30th Sep 2025 7:00 am | RNS | Interim Half Year Results 2025 |
| 15th Sep 2025 7:00 am | RNS | Notice of Interim Results |
| 9th Sep 2025 7:00 am | RNS-R | Shortlisted for AIM Awards Technology of the Year |